These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17516097)

  • 1. Identification of (eta6-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta6-p-cymene)RuCl2 (DMSO)] to stress-regulated proteins and to helicases.
    Will J; Kyas A; Sheldrick WS; Wolters D
    J Biol Inorg Chem; 2007 Aug; 12(6):883-94. PubMed ID: 17516097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry.
    Will J; Sheldrick WS; Wolters D
    J Biol Inorg Chem; 2008 Mar; 13(3):421-34. PubMed ID: 18157731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
    Meier SM; Hanif M; Kandioller W; Keppler BK; Hartinger CG
    J Inorg Biochem; 2012 Mar; 108():91-5. PubMed ID: 22420927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid identification of protein biomarkers of Escherichia coli O157:H7 by matrix-assisted laser desorption ionization-time-of-flight-time-of-flight mass spectrometry and top-down proteomics.
    Fagerquist CK; Garbus BR; Miller WG; Williams KE; Yee E; Bates AH; Boyle S; Harden LA; Cooley MB; Mandrell RE
    Anal Chem; 2010 Apr; 82(7):2717-25. PubMed ID: 20232878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry.
    Will J; Wolters DA; Sheldrick WS
    ChemMedChem; 2008 Nov; 3(11):1696-707. PubMed ID: 18855968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of bindings of organometallic ruthenium complexes to GSTπ by mass spectrometry.
    Lin Y; Huang Y; Zheng W; Wu K; Luo Q; Zhao Y; Xiong S; Wang F
    J Inorg Biochem; 2015 May; 146():44-51. PubMed ID: 25769011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium(II) complexes containing bis(2-(diphenylphosphino)phenyl) ether and their catalytic activity in hydrogenation reactions.
    Venkateswaran R; Mague JT; Balakrishna MS
    Inorg Chem; 2007 Feb; 46(3):809-17. PubMed ID: 17257024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile coordination of acetazolamide to ruthenium(ii) p-cymene complexes and preliminary cytotoxicity studies.
    Biancalana L; Batchelor LK; Ciancaleoni G; Zacchini S; Pampaloni G; Dyson PJ; Marchetti F
    Dalton Trans; 2018 Jul; 47(28):9367-9384. PubMed ID: 29951658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced identification of peptides lacking basic residues by LC-ESI-MS/MS analysis of singly charged peptides.
    Biniossek ML; Schilling O
    Proteomics; 2012 May; 12(9):1303-9. PubMed ID: 22589179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water-soluble ruthenium(II) catalysts [RuCl2(eta6-arene)[P(CH2OH)3]] for isomerization of allylic alcohols and alkyne hydration.
    Cadierno V; Crochet P; García-Garrido SE; Gimeno J
    Dalton Trans; 2004 Nov; (21):3635-41. PubMed ID: 15510287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
    Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
    J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on the interactions of human copper chaperone Cox17 with anticancer organoruthenium(II) complexes and cisplatin by mass spectrometry.
    Li L; Guo W; Wu K; Wu X; Zhao L; Zhao Y; Luo Q; Wang Y; Liu Y; Zhang Q; Wang F
    J Inorg Biochem; 2016 Aug; 161():99-106. PubMed ID: 27235272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes.
    Singh SK; Joshi S; Singh AR; Saxena JK; Pandey DS
    Inorg Chem; 2007 Dec; 46(25):10869-76. PubMed ID: 18001110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Api88 Binding Partners in Escherichia coli Using a Photoaffinity-Cross-Link Strategy and Label-Free Quantification.
    Volke D; Krizsan A; Berthold N; Knappe D; Hoffmann R
    J Proteome Res; 2015 Aug; 14(8):3274-83. PubMed ID: 26196380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
    Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
    J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes.
    Casini A; Mastrobuoni G; Ang WH; Gabbiani C; Pieraccini G; Moneti G; Dyson PJ; Messori L
    ChemMedChem; 2007 May; 2(5):631-5. PubMed ID: 17366652
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
    Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.